The goal of this activity is for learners to be better able to describe prognostic factors that could better identify high-risk patients with T-ALL or T-LL who would benefit from closer follow up or alternative treatment to improve event-free survival (EFS), based on findings from tAALL1231, a Children s Oncology Group (COG) phase 3 clinical trial for children and young adults (age 1-30 years) newly diagnosed with T-ALL or T-LL who were randomized to a modified COG-augmented BFM (aBFM) backbone to receive standard therapy (Arm A) or to aBFM plus bortezomib (Arm B).
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000797
- Start Date: 2024-05-16 05:00:00
- End Date: 2024-05-16 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest